BusinessOpenAI

OpenAI acquires Orchestra Bio to develop biotech AI

Original title: OpenAI acquires startup Orchestra Bio⁠ to beef up its biotech business

Plain language

What it is: OpenAI has acquired Orchestra Bio, a startup that develops software for biotechnology. The acquisition aims to strengthen OpenAI's biotechnology business.
How it works: OpenAI will integrate the team and technology of Orchestra Bio into its own tools. Specifically, they will work on Rosalind, an artificial intelligence model for life sciences, and Rosalind Workbench, a tool for planning experiments.
Where it is available: The technology will be integrated into OpenAI's Rosalind model and the Rosalind Workbench tool.
Example: The technology can be used to manage drug discovery operations, such as tracking finances or resolving scheduling issues in clinical trials.

What it is: OpenAI acquired Orchestra Bio, a startup that builds AI agents for biotechnology operations. The acquisition will support OpenAI's life sciences initiatives.
How it works: Orchestra Bio's team and technology will be integrated into Rosalind, OpenAI's AI model for life sciences research. They will also be added to Rosalind Workbench, a harness used to plan experiments and analyze research results.
Where it is available: The integration applies to OpenAI's Rosalind model and the Rosalind Workbench tool, which are used by clients like Moderna and Novo Nordisk.
Example: Using AI agents to manage drug-discovery operations, including tracking finances and resolving scheduling issues with clinical trials.

The headline and explanation on this page are based on TechCrunch's post. The full details are in the original.

OpenAI acquires startup Orchestra Bio⁠ to beef up its biotech business